SYMBYAX Drug Patent Profile

When do Symbyax patents expire, and what generic alternatives are available?

Symbyax is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in SYMBYAX is fluoxetine hydrochloride; olanzapine. There are twenty-seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride; olanzapine profile page.

Summary for SYMBYAX

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for SYMBYAX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SYMBYAX	Capsules	fluoxetine hydrochloride; olanzapine	6 mg/25 mg 12 mg/25 mg 6 mg/50 mg 12 mg/50 mg	021520	1	2005-01-10

US Patents and Regulatory Information for SYMBYAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-001	Apr 9, 2007		DISCN	Yes	No
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-003	Dec 24, 2003		DISCN	Yes	No
Lilly	SYMBYAX	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	021520-002	Dec 24, 2003		DISCN	Yes	No

International Patents for SYMBYAX

See the table below for patents covering SYMBYAX around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	127804
Australia	643267
Australia	7518691

Supplementary Protection Certificates for SYMBYAX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454436	C970015	Netherlands		PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
0454436	SPC/GB96/058	United Kingdom		PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
0454436	9/1997	Austria		PRODUCT NAME: OLANZAPIN ODER EIN SAEUREADDITIONSSALZ HIEVON; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927

Last updated: February 10, 2026

Investment Scenario and Fundamentals Analysis for SYMBYAX

Overview

SYMBYAX (bupropion/naltrexone) is a prescription medication approved by the FDA in 2014. It combines bupropion, an antidepressant and smoking cessation aid, with naltrexone, an opioid receptor antagonist used in alcohol and opioid dependence. The drug is marketed for weight management and obesity treatment, primarily targeting adults with a BMI of 30 or higher, or 27 with comorbidities.

Market Position and Commercial Performance

Market Size

The global obesity treatment market was valued at approximately $3 billion in 2021. It is projected to grow at a CAGR of 7% to reach $4.65 billion by 2026[1].

Competitive Landscape

SYMBYAX faces competition from established therapies like Wegovy (semaglutide, Novo Nordisk) with $1.9 billion in sales in 2022, and Saxenda (liraglutide, Novo Nordisk). These therapies focus on appetite suppression through GLP-1 receptor agonism, a different mechanism than SYMBYAX.

Prescriber Adoption

Evidence suggests limited prescriber familiarity with SYMBYAX for obesity, given its primary approval was for depression and smoking cessation. Off-label use for weight loss is uncommon, limiting revenue potential.

Development and Regulatory Milestones

• FDA Approval: 2014 for weight management.
• Labeling: Approved with a boxed warning for suicidality related to bupropion.
• Post-Approval: No significant update or label change to expand indications.

Financial and Patent Landscape

Revenue Generation

Eli Lilly, the producer, has not publicly disclosed specific sales figures for SYMBYAX in recent years. Industry estimates suggest sales remain modest, not exceeding $50 million annually globally.

Patent and Exclusivity

The initial composition patent expired in 2020. There is limited data on secondary patents or exclusivity extensions, raising concerns about generic competition.

Investment Risks

• Market Penetration: Limited adoption outside depression treatment reduces revenue streams.
• Regulatory Risks: Potential safety concerns with weight loss drugs could lead to restrictions.
• Competition: Dominance of GLP-1 therapies positions competitors with proven efficacy for weight management.
• Patent Expiry: Eroding IP rights diminish market exclusivity, risking revenue decline.

Growth Opportunities

• Line Extensions: Developing new formulations or additional indications.
• Clinical Trials: Generating data to support label expansions for obesity or other metabolic conditions.
• Strategic Alliances: Partnering for distribution in emerging markets.

Summary of Fundamentals

Aspect	Details
Market Size	$3 billion (2021); potential $4.65 billion by 2026[1]
Market Growth	7% CAGR (2022-2026)
Competitive Position	Low, due to limited prescriber familiarity and competing therapies
Revenue	Estimated below $50 million annually
Patent Status	Expired in 2020, increasing exposure to generics
R&D Investment	Limited; no recent clinical trials for new indications
Regulatory Environment	Stable but safety concerns could impact future approvals

Investment Outlook

The current position of SYMBYAX in the market points to limited growth prospects. The drug’s revenue contribution remains small relative to competitors. Off-label use, patent expiry, and existing safety profiles do not support significant upside. Strategic repositioning or label expansions could change this but are unconfirmed.

Key Takeaways

• SYMBYAX targets the obesity market but has limited commercial success due to market dynamics and competition.
• The product faces patent expiry, with minimal current R&D efforts for new indications.
• Market growth in obesity treatments favors GLP-1 receptor agonists, which dominate sales.
• Risks include market penetration hurdles, safety concerns, and patent expiration.
• Opportunities lie in clinical development for expanded indications and strategic partnerships, though these are uncertain.

FAQs

1. What is the primary FDA-approved use of SYMBYAX?
It is approved for weight management in adults with obesity or overweight with comorbidities, primarily for short-term adjunctive treatment.

2. How does SYMBYAX compare with current obesity therapies?
It has a different mechanism but is less popular and less effective compared to GLP-1 receptor agonists, which currently lead the market.

3. What patent protections exist for SYMBYAX?
The original composition patent expired in 2020. No significant secondary patents or exclusivity extensions are publicly documented.

4. What are the main risks to investing in SYMBYAX?
Limited market adoption, patent expiration, safety profile concerns, and stiff competition from well-established therapies.

5. Are there any plans to expand SYMBYAX's indications?
No publicly announced clinical trials or regulatory submissions for new indications are available.

---

Sources:
[1] MarketData Forecast, 2022.
[2] Eli Lilly financial reports, 2022.